Afanat 40mg contains Afatinib, a targeted cancer therapy used to treat non-small cell lung cancer (NSCLC) that is EGFR mutation-positive.
| Composition | Afatinib |
| Manufacturer | Natco Pharma Ltd |
| Packing | 28 Tablets |
| Prescribed For | Lung Cancer |
| Expiry | December 2027 |
